A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
Carla CalaguaMiriam FicialCaroline S JansenTaghreed HirzLuke Del BalzoScott WilkinsonRoss LakeAnson T KuOlga VoznesenskyDavid B SykesPhilip J SaylorHuihui YeSabina SignorettiHaydn KissickAdam G SowalskySteven P BalkDavid J EinsteinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
A subset of localized prostate cancer is immunogenic, manifested by PD-L1 expression and CD8+ T-cell content comparable with RCC. The CD8+ T cells include effector cells and exhausted progenitor cells, which may be expanded by immune checkpoint inhibitors (ICI). Genomic losses of RB1, BRCA2, and CHD1 may be drivers of this phenotype. These findings indicate that immunotherapies may be effective in biomarker-selected subpopulations of patients with localized prostate cancer.